Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan.
DeGruttola V, Dix L, D'Aquila R, Holder D, Phillips A, Ait-Khaled M, Baxter J, Clevenbergh P, Hammer S, Harrigan R, Katzenstein D, Lanier R, Miller M, Para M, Yerly S, Zolopa A, Murray J, Patick A, Miller V, Castillo S, Pedneault L, Mellors J. DeGruttola V, et al. Among authors: pedneault l. Antivir Ther. 2000 Mar;5(1):41-8. doi: 10.1177/135965350000500112. Antivir Ther. 2000. PMID: 10846592
Antiretroviral resistance testing comes of age.
Hammer SM, Pedneault L. Hammer SM, et al. Among authors: pedneault l. Antivir Ther. 2000 Mar;5(1):23-6. Antivir Ther. 2000. PMID: 10846589 No abstract available.
Amprenavir in combination with lamivudine and zidovudine versus lamivudine and zidovudine alone in HIV-1-infected antiretroviral-naive adults. Amprenavir PROAB3001 International Study Team.
Goodgame JC, Pottage JC Jr, Jablonowski H, Hardy WD, Stein A, Fischl M, Morrow P, Feinberg J, Brothers CH, Vafidis I, Nacci P, Yeo J, Pedneault L. Goodgame JC, et al. Among authors: pedneault l. Antivir Ther. 2000 Sep;5(3):215-25. Antivir Ther. 2000. PMID: 11075942 Clinical Trial.
Metabolic complications associated with antiretroviral therapy.
Jain RG, Furfine ES, Pedneault L, White AJ, Lenhard JM. Jain RG, et al. Among authors: pedneault l. Antiviral Res. 2001 Sep;51(3):151-77. doi: 10.1016/s0166-3542(01)00148-6. Antiviral Res. 2001. PMID: 11448728 Review.
Induction of strong HIV-1-specific CD4+ T-cell responses using an HIV-1 gp120/NefTat vaccine adjuvanted with AS02A in antiretroviral-treated HIV-1-infected individuals.
Lichterfeld M, Gandhi RT, Simmons RP, Flynn T, Sbrolla A, Yu XG, Basgoz N, Mui S, Williams K, Streeck H, Burgett-Yandow N, Roy G, Janssens M, Pedneault L, Vandepapelière P, Koutsoukos M, Demoitié MA, Bourguignon P, McNally L, Voss G, Altfeld M. Lichterfeld M, et al. Among authors: pedneault l. J Acquir Immune Defic Syndr. 2012 Jan 1;59(1):1-9. doi: 10.1097/QAI.0b013e3182373b77. J Acquir Immune Defic Syndr. 2012. PMID: 21963936 Free PMC article. Clinical Trial.
Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant Systems.
Leroux-Roels I, Koutsoukos M, Clement F, Steyaert S, Janssens M, Bourguignon P, Cohen K, Altfeld M, Vandepapelière P, Pedneault L, McNally L, Leroux-Roels G, Voss G. Leroux-Roels I, et al. Among authors: pedneault l. Vaccine. 2010 Oct 8;28(43):7016-24. doi: 10.1016/j.vaccine.2010.08.035. Epub 2010 Aug 20. Vaccine. 2010. PMID: 20728522 Clinical Trial.
Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers.
Goepfert PA, Tomaras GD, Horton H, Montefiori D, Ferrari G, Deers M, Voss G, Koutsoukos M, Pedneault L, Vandepapeliere P, McElrath MJ, Spearman P, Fuchs JD, Koblin BA, Blattner WA, Frey S, Baden LR, Harro C, Evans T; NIAID HIV Vaccine Trials Network. Goepfert PA, et al. Among authors: pedneault l. Vaccine. 2007 Jan 5;25(3):510-8. doi: 10.1016/j.vaccine.2006.07.050. Epub 2006 Aug 10. Vaccine. 2007. PMID: 17049679 Clinical Trial.
39 results